NAFLD in women: Unique pathways, biomarkers and therapeutic opportunities.
NAFLD in women: Unique pathways, biomarkers and therapeutic opportunities.
复制标题
DOI：
10.1007/s11901-019-00495-9
复制
发表时间：
2019-12-01
期刊：
影响因子：
--
通讯作者：
Sarkar, Monika
中科院分区：
文献类型：
--
作者：
Yuan, Liyun;Kardashian, Ani;Sarkar, Monika
综述目的：在这篇综述文章中，我们评估了NAFLD自然史中的性别差异，强调了NAFLD女性的独特风险特征，以及独特的治疗考虑和研究空白。研究结果总结：在评估女性NAFLD风险时，应考虑生殖因素，如绝经状态，以及其他生殖风险因素，如初潮年龄、多囊卵巢综合征和妊娠糖尿病。与男性相比，女性患NASH肝细胞癌的风险更低，NASH肝硬化的死亡率也更低，尽管在女性中，NASH现在是肝移植的主要适应症。关于生物标志物发展和临床试验中性别差异的数据缺乏，应该鼓励研究人员按性别评估生物标志物的表现，并特别报告女性的临床试验终点。
PURPOSE OF REVIEW: In this review article we evaluate sex differences in the natural history of NAFLD and highlight distinct risk profiles of women with NAFLD, as well as unique treatment considerations and research gaps.SUMMARY OF FINDINGS: Reproductive factors, such as menopausal status should be considered when evaluating NAFLD risk in women, as well as additional reproductive risk factors such as age at menarche, presence of polycystic ovary syndrome, and gestational diabetes. Women do appear to have lower risk for hepatocellular carcinoma from NASH, as well as lower mortality from NASH cirrhosis than men, although among women, NASH is now the leading indication for liver transplant. Data on sex differences in biomarker development and clinical trials are lacking, and researchers should be encouraged to evaluate biomarker performance by sex, and specifically report clinical trial endpoints in women.